The experience of key technical personnel who will be responsible for the day-to-day operation: Meharry Principal Investigator: Billy R. Ballard, DDS, MD, is board-certified pathologist. Professor and Chair of the Department of Pathology at Meharry Medical College. Dr. Ballard has more than 40 years experience as a general surgical and cytopathologist with special interest and experts in head and neck, genitourinary, breast, gynecologic, and soft tissue pathology. Dr. Ballard will be responsible for refining the laboratory procedures, hiring personnel, managing the budget, evaluafing and selecting equipment for the laboratory. In addition. Dr. Ballard will be responsible for ensuring the laboratory meets the needs of Partnership investigators. This will be accomplished by interacting closely with the Histopathology Core Internal and External Advisory Committees, which has the responsibility for oversight ofthe core and with the Human Tissue Acquisition and Pathology Core at VICC. The oversight committees will assist with the development and implementation of operational policies and procedures for the core including the development of fee schedules, development and implementation of new procedures or tests, the prioritization and allocation of banked samples, and the selection of pilot studies that to receive fee weavers or a reducfion, and others as the need arises. A close working relationship will be established and maintained to assure that we address the needs of the investigators ufilizing services of the core. An addifional responsibility shall include interacting with principle investigators in developing specific tissue collection protocols available for any technical or scienfific questions concerning tissue procurement. He is responsible for Increasing awareness and availability of this Core the Partnership research community by giving a series of seminars to various groups concerning operafion and services.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Meharry Medical College
United States
Zip Code
Pellom Jr, Samuel T; Dudimah, Duafalia F; Thounaojam, Menaka C et al. (2017) Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function. Oncotarget 8:8604-8621
Hull, Pamela; Emerson, Janice S; Quirk, Meghan E et al. (2017) A Smartphone App for Families With Preschool-Aged Children in a Public Nutrition Program: Prototype Development and Beta-Testing. JMIR Mhealth Uhealth 5:e102
Schlundt, David; Briley, Chiquita; Canada, Barbara et al. (2017) Availability of Low-Fat Milk and Produce in Small and Mid-Sized Grocery Stores After 2014 WIC Final Rule Changes, Tennessee. Prev Chronic Dis 14:E70
Uzhachenko, Roman; Boyd, Kelli; Olivares-Villagomez, Danyvid et al. (2017) Mitochondrial protein Fus1/Tusc2 in premature aging and age-related pathologies: critical roles of calcium and energy homeostasis. Aging (Albany NY) 9:627-649
Choi, Hyeongjwa; Ignacio, Rosa Mistica C; Lee, Eun-Sook et al. (2017) Augmented Serum Amyloid A1/2 Mediated by TNF-induced NF-?B in Human Serous Ovarian Epithelial Tumors. Immune Netw 17:121-127
Brown, Shyretha; Tehrani, Shahin; Whalen, Margaret M (2017) Dibutyltin-induced alterations of interleukin 1beta secretion from human immune cells. J Appl Toxicol 37:181-191
Pellom Jr, Samuel T; Singhal, Ashutosh; Shanker, Anil (2017) Prospects of combining adoptive cell immunotherapy with bortezomib. Immunotherapy 9:305-308
Amara, Suneetha; Tiriveedhi, Venkataswarup (2017) The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy. Int J Mol Sci 18:
Shanker, Anil; Thounaojam, Menaka C; Mishra, Manoj K et al. (2017) Innate-Adaptive Immune Crosstalk 2016. J Immunol Res 2017:3503207
Selove, Rebecca; Foster, Maya; Wujcik, Debra et al. (2017) Psychosocial concerns and needs of cancer survivors treated at a comprehensive cancer center and a community safety net hospital. Support Care Cancer 25:895-904

Showing the most recent 10 out of 148 publications